Tema ETFs LLC Takes $964,000 Position in Inhibrx Biosciences, Inc. $INBX

Tema ETFs LLC purchased a new position in Inhibrx Biosciences, Inc. (NASDAQ:INBX) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 10,170 shares of the company’s stock, valued at approximately $964,000. Tema ETFs LLC owned approximately 0.07% of Inhibrx Biosciences at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. grew its position in Inhibrx Biosciences by 26.3% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 707 shares of the company’s stock valued at $56,000 after purchasing an additional 147 shares in the last quarter. Persistent Asset Partners Ltd purchased a new stake in Inhibrx Biosciences in the 4th quarter worth approximately $27,000. BNP Paribas Financial Markets lifted its position in Inhibrx Biosciences by 71.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,886 shares of the company’s stock worth $64,000 after buying an additional 789 shares in the last quarter. Daiwa Securities Group Inc. acquired a new stake in shares of Inhibrx Biosciences during the 4th quarter valued at $66,000. Finally, Janney Montgomery Scott LLC boosted its stake in shares of Inhibrx Biosciences by 16.6% during the 1st quarter. Janney Montgomery Scott LLC now owns 6,406 shares of the company’s stock valued at $431,000 after buying an additional 911 shares during the period. 82.46% of the stock is currently owned by institutional investors and hedge funds.

Inhibrx Biosciences Trading Down 1.4%

Shares of NASDAQ:INBX opened at $97.01 on Friday. The stock has a market capitalization of $1.42 billion, a PE ratio of -11.56 and a beta of 3.51. Inhibrx Biosciences, Inc. has a 1 year low of $22.40 and a 1 year high of $155.29. The firm has a fifty day moving average price of $90.85 and a 200 day moving average price of $88.48. The company has a current ratio of 6.46, a quick ratio of 6.46 and a debt-to-equity ratio of 12.58.

Inhibrx Biosciences (NASDAQ:INBX) last posted its earnings results on Thursday, August 13th. The company reported ($2.34) earnings per share for the quarter, missing the consensus estimate of ($2.28) by ($0.06). Analysts expect that Inhibrx Biosciences, Inc. will post -10.15 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inhibrx Biosciences in a research note on Tuesday, June 16th. Wall Street Zen raised Inhibrx Biosciences from a “sell” rating to a “hold” rating in a research report on Sunday, August 9th. Finally, Lifesci Capital upgraded Inhibrx Biosciences to a “strong-buy” rating in a research note on Friday, April 24th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $150.00.

About Inhibrx Biosciences

Inhibrx, Inc, headquartered in La Jolla, California, is a clinical-stage biotechnology company focused on the discovery and development of next-generation protein therapeutics. The company’s proprietary protein engineering platform enables the design and production of multispecific and multivalent biologics with tailored binding characteristics and favorable pharmacokinetic properties. By leveraging high-throughput screening and structure-based design, Inhibrx aims to create molecules that address challenging targets in oncology, regenerative medicine and other areas of unmet medical need.

The company’s lead candidate, INBRX-109, is a tetravalent agonist of the receptor tyrosine kinase ROR2 designed to stimulate tissue repair and regeneration.